Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.

Rissel, Florian; Cazaubon, Yoann; Saffar, Syrine; Altwegg, Romain; Artasone, Mélanie; Lozano, Claire; Vincent, Thierry; Jentzer, Alexandre

Rissel, Florian; Cazaubon, Yoann; Saffar, Syrine; Altwegg, Romain; Artasone, Mélanie; Lozano, Claire; Vincent, Thierry; Jentzer, Alexandre.

Afiliação

Rissel F; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Cazaubon Y; Institute Desbrest of Epidemiology and Public Health, Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pharmacology and Toxicology, Montpellier University Hospital, Montpellier University, 34090 Montpellier, France.
Saffar S; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Altwegg R; Department of Hepato-Gastroenterology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Artasone M; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Lozano C; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Vincent T; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.
Jentzer A; Department of Immunology, Saint Eloi, Montpellier University Hospital, Montpellier University, 34295 Montpellier, France.

Int J Mol Sci ; 24(12)2023 Jun 20.

Article em En | MEDLINE | ID: mdl-37373525

Assuntos

Monitoramento de Medicamentos; Doenças Inflamatórias Intestinais; Humanos; Infliximab/uso terapêutico; Adalimumab/uso terapêutico; Monitoramento de Medicamentos/métodos; Inibidores do Fator de Necrose Tumoral/uso terapêutico; Imunoensaio; Ensaio de Imunoadsorção Enzimática/métodos; Fator de Necrose Tumoral alfa/uso terapêutico; Doenças Inflamatórias Intestinais/tratamento farmacológico

Palavras-chave

adalimumab; antidrug antibodies; immunoassays comparison; infliximab; therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Monitoramento de Medicamentos Tipo de estudo: Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google